BR112022016370A2 - Métodos para reduzir a expressão de htt - Google Patents

Métodos para reduzir a expressão de htt

Info

Publication number
BR112022016370A2
BR112022016370A2 BR112022016370A BR112022016370A BR112022016370A2 BR 112022016370 A2 BR112022016370 A2 BR 112022016370A2 BR 112022016370 A BR112022016370 A BR 112022016370A BR 112022016370 A BR112022016370 A BR 112022016370A BR 112022016370 A2 BR112022016370 A2 BR 112022016370A2
Authority
BR
Brazil
Prior art keywords
reduce
methods
huntington
disease
reduce htt
Prior art date
Application number
BR112022016370A
Other languages
English (en)
Portuguese (pt)
Inventor
Frank Bennett C
A Norris Daniel
V Smith Anne
Lane Roger
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of BR112022016370A2 publication Critical patent/BR112022016370A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
BR112022016370A 2020-02-21 2021-02-19 Métodos para reduzir a expressão de htt BR112022016370A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062980010P 2020-02-21 2020-02-21
PCT/US2021/018681 WO2021168183A1 (en) 2020-02-21 2021-02-19 Methods for reducing htt expression

Publications (1)

Publication Number Publication Date
BR112022016370A2 true BR112022016370A2 (pt) 2022-10-04

Family

ID=77391689

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016370A BR112022016370A2 (pt) 2020-02-21 2021-02-19 Métodos para reduzir a expressão de htt

Country Status (12)

Country Link
US (2) US20230108340A1 (enExample)
EP (1) EP4107269A4 (enExample)
JP (2) JP2023515466A (enExample)
KR (1) KR20220144837A (enExample)
CN (1) CN115279903A (enExample)
AU (1) AU2021224729A1 (enExample)
BR (1) BR112022016370A2 (enExample)
CA (1) CA3172336A1 (enExample)
IL (1) IL295625A (enExample)
MX (1) MX2022010204A (enExample)
WO (1) WO2021168183A1 (enExample)
ZA (1) ZA202209112B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025265013A2 (en) 2024-06-20 2025-12-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422819B1 (en) * 2006-01-26 2017-03-01 Ionis Pharmaceuticals, Inc. Compositions and their uses directed to Huntingtin
EP3626823A1 (en) * 2009-09-11 2020-03-25 Ionis Pharmaceuticals, Inc. Modulation of huntingtin expression
WO2015051318A1 (en) * 2013-10-04 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
US20170044538A1 (en) * 2014-04-17 2017-02-16 Biogen Ma Inc. Compositions and Methods for Modulation of SMN2 Splicing in a Subject
CN117965536A (zh) * 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
US11268093B2 (en) * 2017-01-03 2022-03-08 Rula Zain-Luqman Therapeutic method for huntington's disease
KR20220030271A (ko) * 2019-06-28 2022-03-10 더 펜 스테이트 리서어치 파운데이션 헌팅턴병을 치료하기 위한 방법 및 재료

Also Published As

Publication number Publication date
IL295625A (en) 2022-10-01
MX2022010204A (es) 2022-09-19
US20230108340A1 (en) 2023-04-06
EP4107269A4 (en) 2024-11-20
JP2023515466A (ja) 2023-04-13
ZA202209112B (en) 2024-10-30
KR20220144837A (ko) 2022-10-27
US20260234628A1 (en) 2026-08-13
CA3172336A1 (en) 2021-08-26
EP4107269A1 (en) 2022-12-28
JP2026075094A (ja) 2026-05-07
CN115279903A (zh) 2022-11-01
WO2021168183A1 (en) 2021-08-26
AU2021224729A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
Sung et al. Efficacy of forced-use therapy in hemiplegic cerebral palsy
Marchisio et al. Accelerated rehabilitation versus conventional rehabilitation in total hip arthroplasty (ARTHA): a randomized double blinded clinical trial
Finkel et al. FP. 24 RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)
Yonekawa et al. Extremely severe complicated spastic paraplegia 3A with neonatal onset
MX2023008922A (es) Compuestos y metodos para modular la huntingina.
Pardeshi et al. Importance of nanomedicine in human health
ZA202209112B (en) Methods for reducing htt expression
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
Apostolopoulos Stretch intensity and the inflammatory response: a paradigm shift
Gourie-Devi et al. Madras motor neuron disease variant, clinical features of seven patients
Modesto et al. Comparison of functional electrical stimulation associated with kinesiotherapy and kinesiotherapy alone in patients with hemiparesis during the subacute phase of ischemic cerebrovascular accident
Somerville et al. Valproic acid: treatment of myoclonus in dyssynergia cerebellaris myoclonica
Pérez-Carbonell et al. Periodic neck myoclonus during sleep
BR112021017961A2 (pt) Combinação de agentes antivirais, kit e método de tratamento com base nos mesmos
Baladaniya et al. Impact of physical therapy on empowering neurological aging: a narrative review
Fotiadis et al. Hemiplegic shoulder syndrome: Possible underlying neurophysiological mechanisms
Fonseca et al. Charcot-Marie-Tooth Disease
Flensmark Physical activity, eccentric contractions of plantar flexors, and neurogenesis: Therapeutic potential of flat shoes in psychiatric and neurological disorders
Ornsteen The syndrome of amyotrophic lateral sclerosis in epidemic encephalitis
Dhawale et al. Effect of trunk control exercises on balance and gait in stroke patients-randomized control trial
Koloskova et al. Comprehensive rehabilitation of a child with organic pathology, own clinical experience.
Paliwal Neuromyotonia masquerading as tetanus
Dwijayanti et al. Brain derived neurotrophic factor levels in aged rats post-systemic human mesenchymal stem cell administration
Kubota et al. Spontaneous and reflex movements after diagnosis of clinical brain death: A lesson from acute encephalopathy
LE OPEN POST-POLIO SYNDROME AND THE POLIOMYELITIS: A

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]